Tocqueville Asset Management L.P. decreased its position in Edwards Lifesciences Corp (NYSE:EW) by 0.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,430 shares of the medical research company’s stock after selling 365 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Edwards Lifesciences were worth $7,561,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Honkamp Krueger Financial Services Inc. acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $106,000. SRS Capital Advisors Inc. grew its position in shares of Edwards Lifesciences by 317.5% in the 3rd quarter. SRS Capital Advisors Inc. now owns 668 shares of the medical research company’s stock worth $116,000 after acquiring an additional 508 shares in the last quarter. LFA Lugano Financial Advisors SA acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $121,000. Prime Capital Investment Advisors LLC grew its position in shares of Edwards Lifesciences by 577.9% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 705 shares of the medical research company’s stock worth $123,000 after acquiring an additional 601 shares in the last quarter. Finally, Private Capital Group LLC acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $112,000. Institutional investors own 82.55% of the company’s stock.
NYSE:EW opened at $157.21 on Friday. Edwards Lifesciences Corp has a 12-month low of $110.68 and a 12-month high of $175.00. The company has a market cap of $34.14 billion, a P/E ratio of 41.37, a P/E/G ratio of 2.15 and a beta of 0.90. The company has a quick ratio of 1.85, a current ratio of 2.31 and a debt-to-equity ratio of 0.18.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The business had revenue of $906.60 million during the quarter, compared to analyst estimates of $927.56 million. During the same quarter in the previous year, the firm posted $0.84 EPS. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. Equities analysts expect that Edwards Lifesciences Corp will post 4.7 EPS for the current fiscal year.
In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,500 shares of the business’s stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $144.16, for a total transaction of $792,880.00. Following the completion of the transaction, the vice president now owns 25,490 shares in the company, valued at approximately $3,674,638.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Huimin Wang sold 3,800 shares of the business’s stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $155.87, for a total value of $592,306.00. Following the transaction, the vice president now owns 35,024 shares of the company’s stock, valued at approximately $5,459,190.88. The disclosure for this sale can be found here. Insiders have sold a total of 187,156 shares of company stock valued at $27,603,513 in the last quarter. 1.84% of the stock is currently owned by insiders.
Several brokerages have recently commented on EW. Zacks Investment Research lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, October 25th. Royal Bank of Canada boosted their price objective on Edwards Lifesciences to $175.00 and gave the company an “outperform” rating in a research report on Thursday. Raymond James boosted their price objective on Edwards Lifesciences from $160.00 to $175.00 and gave the company an “outperform” rating in a research report on Thursday. Stifel Nicolaus restated a “positive” rating on shares of Edwards Lifesciences in a research report on Thursday. Finally, Cowen set a $190.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday, November 30th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $162.85.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Read More: Swap
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.